Serlopitant and Eczema Itch: A 484-Person Trial Did Not Reproduce the Broader Chronic-Itch Signal
DOCTOR’S NOTES · ECZEMA EVIDENCE
Itch is a symptom shared by several conditions, so a positive chronic-itch study does not automatically show that a medicine works for eczema. Serlopitant is an instructive example: its eczema-specific trial was larger than many early reports, yet it did not establish the hoped-for benefit.
The eczema-specific comparison
Menlo’s April 8, 2018 primary company disclosure, filed with the SEC, reports ATOMIK: 484 participants aged 13 or older with past or present atopic dermatitis and significant itch. They received placebo, 1 mg or 5 mg serlopitant daily for six weeks. The primary outcome was change in worst-itch score.
| Week-six result | Placebo | 1 mg | 5 mg |
|---|---|---|---|
| Mean worst-itch score change | −2.01 | −2.32 | −2.25 |
| At least four-point itch improvement | 16.5% | 22.4% | 20.6% |
The study missed its primary and key secondary endpoints. The four-point-response comparisons had P=.09 and P=.17. Numerical improvement favoring active treatment was not a statistically established benefit. This is sponsor-reported top-line evidence, rather than a claim that a full eczema trial paper was reviewed.
Why another itch trial does not settle this question
A separate 2018 primary chronic-pruritus abstract reported significant six-week results with 1- and 5-mg doses. It also states that sample size was insufficient to analyze efficacy by underlying condition. Therefore, that broader study cannot supply an eczema-specific success claim that ATOMIK did not demonstrate.
The distinction is about the population, not about dismissing anyone’s itch. Studies can differ in causes of symptoms, background care, entry severity, outcome definitions and response to study participation. A medicine can show a signal in one setting without reproducing it in another. A shared biological pathway does not remove the need for the condition-specific comparison.
Read the treatment effect, not only the change
Every group’s mean itch score fell in ATOMIK. The added effect asks how much more the active group changed than placebo, with uncertainty considered. Copying only the larger before-and-after change into a caption would make the evidence look stronger than its actual conclusion. The responder analysis likewise needs the comparator and its nonsignificant result attached.
What to bring to an itch consultation
Describe how often itch interrupts sleep, concentration or activity, and distinguish the worst episode from the average day. Ask which outcome will guide treatment decisions and when the current plan should be reviewed. A modest-looking rash can still have a large effect on function; the symptom report deserves attention without requiring a favorable experimental-drug headline.
The AAD guideline hub provides the broader clinical context. The historical trial doses here are not instructions to seek serlopitant or substitute it for prescribed care.
How another itch-support study requires caution about tiny groups and descriptive results
Where moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not tested in the research discussed here. These findings do not establish pediatric efficacy or infant suitability for #003; ask a child’s clinician about an appropriate moisturizer.
Continue with a related question
- How to Read an Eczema Study Without Getting Misled by Percentages
- Your Eczema Itch Score and Your Rash Score Can Tell Different Stories
- What Is SCORAD? Understanding an Eczema Severity Score
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational content does not diagnose an individual or imply independent medical review. Cited researchers and institutions do not endorse #003. Image is an AI-created editorial product illustration, not a patient photograph or clinical result.